Monday, July 14, 1997
Emerging Company Profile
RedCell: Permanent bonds
Many drugs fail in development because they are rapidly metabolized or cleared from the body too rapidly to have a therapeutic effect. Others must be given at such high doses that they cause toxicities and side effects.
RedCell Canada Inc. is combining the body's natural delivery packages - plasma proteins and red blood cells (RBCs) - with its Anchor chemistries to permanently bind therapeutic agents to the natural carriers in vivo. The company's goal is to increase the half-life of the anchored drug by several hundred-fold, giving the bound drug the carrier's own distribution characteristics. The potential benefits of such a system include a longer duration of action, controlled distribution, decreased frequency of administration and increased compliance.
RedCell's Anchors are small molecules designed to link drug and carriers. The tether between the drug and the affinity group that forms the targeting/bonding end of the